Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aviron FluMist Initial Indication May Exclude Youngest Children, CEO Says

Executive Summary

Aviron is willing to change the proposed pediatric indication for its intranasal flu vaccine FluMist if that would hasten FDA approval, CEO Boyd Clarke told analysts July 30.
Advertisement

Related Content

Lilly Forteo Follow-Up Rat Osteosarcoma Study To Finish By End Of 2002
Wyeth/Aviron FluMist Pulmonary Safety Requires More Analysis - FDA Cmte.
Wyeth/Aviron FluMist Pulmonary Safety Requires More Analysis - FDA Cmte.
Advertisement
UsernamePublicRestriction

Register

PS038282

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel